The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy
Open accessAbstract
Phosphatidylinositol 3‐kinases (PI3K) are a group of lipid kinases that phosphorylate phosphoinositides at the 3‐hydroxyl group of the inositol ring to generate phosphatidylinositol 3,4,5‐trisphosphate, a second messenger with key roles in fundamental cellular responses such as cell proliferation and metabolism. Frequent mutations found in or amplification of the PIK3CA gene and loss of phosphatase and tensin homolog deleted on chromosome 10 function in human tumors suggest that PI3K is a potential target for cancer therapy. During the last 5 years, several specific PI3K inhibitors were developed that were directed against various diseases. Some of them revealed potent anticancer efficacy and are now undergoing clinical trials. Some PI3K inhibitors showed antiangiogenic effects. Combined use of PI3K inhibitors with other chemotherapeutic agents or with radiotherapy produced synergistic therapeutic efficacies in treating cancer and showed reduced side effects. The rapid progress made in developing novel PI3K inhibitors in recent years promises bright prospects for finding a PI3K‐targeted anticancer drug in the near future. (Cancer Sci 2008; 99: 1734–1740)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
Synthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling
SHEPHERD, P. R., WITHERS, D. J., & SIDDLE, K. (1998) · Biochemical Journal · doi:10.1042/bj3330471 · Cited by 953
Signalling through Class I PI3Ks in mammalian cells
Hawkins, P. T., Anderson, K. E., Davidson, K., & Stephens, L. R. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340647 · Cited by 540
Research works printed but not linked: 89
- 10.1038/42648 · DOI · Paper page
- 10.1016/S0968-0004(97)01061-X · DOI · Paper page
- 10.1038/332644a0 · DOI · Paper page
- 10.1016/S0092-8674(00)81883-8 · DOI · Paper page
- 10.1016/S1357-2725(02)00270-4 · DOI
- 10.1016/S1357-4310(00)01770-6 · DOI · Paper page
- 10.1016/j.ctrv.2003.07.007 · DOI · Paper page
- 10.1016/S0005-2760(98)00139-8 · DOI · Paper page
- 10.1034/j.1600-0854.2002.30605.x · DOI · Paper page
- 10.1038/12075 · DOI · Paper page
- 10.1038/nrd1902 · DOI · Paper page
- 10.1016/j.tibs.2005.02.008 · DOI · Paper page
- 10.1074/jbc.272.31.19236 · DOI · Paper page
- 10.1073/pnas.94.9.4330 · DOI · Paper page
- 10.1126/science.1096502 · DOI · Paper page
- 10.1158/1078-0432.CCR-04-2142 · DOI · Paper page
- 10.1016/j.bbrc.2005.12.025 · DOI
- 10.1016/j.cell.2006.03.035 · DOI · Paper page
- 10.1038/nm1232 · DOI · Paper page
- 10.1126/science.287.5455.1049 · DOI · Paper page
- 10.1126/science.287.5455.1046 · DOI · Paper page
- 10.1126/science.287.5455.1040 · DOI · Paper page
- 10.1038/nm1291 · DOI · Paper page
- 10.1038/nm1284 · DOI · Paper page
- 10.4049/jimmunol.170.5.2647 · DOI · Paper page
- 10.1038/nature02369 · DOI · Paper page
- 10.2174/156652405774641034 · doi:10.2174/156652405774641034
- 10.1074/jbc.M404097200 · DOI · Paper page
- 10.1083/jcb.200403069 · DOI · Paper page
- 10.1016/j.ccr.2005.08.008 · DOI · Paper page
- 10.1016/j.ccr.2006.05.002 · doi:10.1016/j.ccr.2006.05.002
- 10.1158/0008-5472.CAN-05-0917 · DOI · Paper page
- 10.1038/46319 · DOI · Paper page
- 10.1016/S1097-2765(05)00089-4 · DOI · Paper page
- 10.1016/S0006-291X(84)80264-8 · DOI
- 10.1016/0006-291X(85)91761-9 · DOI
- 10.1016/0006-291X(83)91220-2 · DOI
- 10.1016/0006-2952(82)90028-4 · DOI
- 10.1111/j.1432-1033.1983.tb07692.x · DOI · Paper page
- 10.1016/S0021-9258(17)37680-9 · DOI · Paper page
- 10.1042/bj3510095 · DOI · Paper page
- Hu L, 2000, In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3‐kinase inhibitor (LY294002), Clin Cancer Res, 6, 880
- 10.1016/S0007-1536(57)80033-3 · doi:10.1016/s0007-1536(57)80033-3
- 10.1039/c39720001061 · doi:10.1039/c39720001061
- 10.1007/BF01927691 · DOI
- Powis G, 1994, Wortmannin, a potent and selective inhibitor of phosphatidylinositol‐3‐kinase, Cancer Res, 54, 2419
- 10.1016/S0021-9258(17)41900-4 · DOI · Paper page
- 10.1042/bj2960297 · DOI · Paper page
- 10.1016/S0021-9258(18)45857-7 · DOI · Paper page
- 10.1128/MCB.16.4.1722 · DOI · Paper page
- Ihle NT, 2004, Molecular pharmacology and antitumor activity of PX‐866, a novel inhibitor of phosphoinositide‐3‐kinase signaling, Mol Cancer Ther, 3, 763, 10.1158/1535-7163.763.3.7 · DOI · Paper page
- 10.1158/1535-7163.MCT-05-0149 · DOI
- 10.1182/blood-2003-05-1667 · DOI · Paper page
- 10.1096/fj.05-5045com · DOI · Paper page
- 10.1182/blood-2004-08-3225 · DOI · Paper page
- 10.1038/sj.onc.1209670 · DOI
- 10.1073/pnas.0606956103 · DOI
- 10.1016/j.ccr.2006.03.029 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-2154 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-4615 · DOI · Paper page
- Stauffer FG‐EC, 2007, Proceedings of American Association for Cancer Research
- 10.1158/0008-5472.CAN-07-0669 · DOI · Paper page
- 10.1093/jnci/djj133 · DOI · Paper page
- 10.1111/j.1349-7006.2007.00580.x · DOI · Paper page
- 10.1002/jcp.20707 · DOI
- 10.1073/pnas.081063798 · DOI · Paper page
- 10.1074/jbc.M110219200 · DOI · Paper page
- 10.1159/000046610 · DOI · Paper page
- Jiang BH, 2001, Phosphatidylinositol 3‐kinase signaling controls levels of hypoxia‐inducible factor 1, Cell Growth Differ, 12, 363
- 10.1038/ncb1695 · DOI · Paper page
- 10.1016/j.devcel.2005.08.001 · DOI · Paper page
- 10.1073/pnas.040560897 · DOI · Paper page
- 10.1016/j.cellsig.2007.07.025 · DOI · Paper page
- Su JD, 2003, PTEN and phosphatidylinositol 3′‐kinase inhibitors up‐regulate p53 and block tumor‐induced angiogenesis: evidence for an effect on the tumor and endothelial compartment, Cancer Res, 63, 3585
- Hu L, 2002, Inhibition of phosphatidylinositol 3′‐kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models, Cancer Res, 62, 1087
- Asselin E, 2001, XIAP regulates Akt activity and caspase‐3‐dependent cleavage during cisplatin‐induced apoptosis in human ovarian epithelial cancer cells, Cancer Res, 61, 1862
- 10.1182/blood.V86.2.726.bloodjournal862726 · DOI · Paper page
- 10.1182/blood-2002-11-3429 · DOI · Paper page
- 10.1038/sj.onc.1205724 · DOI
- 10.1182/blood-2007-09-114454 · DOI
- 10.1016/j.ctrv.2006.01.003 · DOI · Paper page
- 10.1007/s00401-005-1001-0 · DOI
- Fan QW, 2003, Combinatorial efficacy achieved through two‐point blockade within a signaling pathway – a chemical genetic approach, Cancer Res, 63, 8930
- Sarkaria JN, 1998, Inhibition of phosphoinositide 3‐kinase related kinases by the radiosensitizing agent wortmannin, Cancer Res, 58, 4375
- Rosenzweig KE, 1997, Radiosensitization of human tumor cells by the phosphatidylinositol3‐kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA‐dependent protein kinase and prolonged G2–M delay, Clin Cancer Res, 3, 1149
- 10.1073/pnas.0510772103 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-0152 · DOI
- 10.1126/science.7701324 · DOI · Paper page
- 10.1038/sj.onc.1207115 · DOI · Paper page
Cited by
Wu, Y.-T., Tan, H.-L., Shui, G., Bauvy, C., Huang, Q., Wenk, M. R., Ong, C.-N., Codogno, P., & Shen, H.-M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.080796 · Cited by 1,127
Finding of Rare Disease Genes (FORGE) Canada Consortium, Rivière, J.-B., Mirzaa, G. M., O'Roak, B. J., Beddaoui, M., Alcantara, D., Conway, R. L., St-Onge, J., Schwartzentruber, J. A., Gripp, K. W., et al. (2012) · Nature Genetics · doi:10.1038/ng.2331 · Cited by 741
Kaempferol and inflammation: from chemistry to medicine
Devi, K. P., Malar, D. S., Nabavi, S. F., Sureda, A., Xiao, J., Nabavi, S. M., & Daglia, M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.002 · Cited by 619
Targeting autophagy in ischemic stroke: From molecular mechanisms to clinical therapeutics
Ajoolabady, A., Wang, S., Kroemer, G., Penninger, J. M., Uversky, V. N., Pratico, D., Henninger, N., Reiter, R. J., Bruno, A., Joshipura, K., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107848 · Cited by 333
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Mishra, R., Patel, H., Alanazi, S., Kilroy, M. K., & Garrett, J. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073464 · Cited by 281
Metadata
- Authors
- Kong, D., & Yamori, T.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2008-08-21
- Volume
- 99
- Issue
- 9
- Pages
- 1734-1740
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2088118561
- Cited by
- 184
- References
- 7
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy. https://app.cochat.ai/papers/10.1111/j.1349-7006.2008.00891.x
- The paper
- Kong, D., & Yamori, T. (2008). Phosphatidylinositol 3‐kinase inhibitors: promising drug candidates for cancer therapy. Cancer Science. https://doi.org/10.1111/j.1349-7006.2008.00891.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.